Phase I/II Trial Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC
Phase of Trial: Phase I/II
Latest Information Update: 10 Sep 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Selumetinib (Primary) ; Tremelimumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Sep 2019 Trial design presented at the 20th World Conference on Lung Cancer
- 02 May 2019 Status changed from not yet recruiting to recruiting.
- 08 Feb 2019 Planned End Date changed from 16 Apr 2020 to 16 Apr 2021.